Glaxosmithkline Capital 6-K Current report (foreign)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

Report of Foreign Private Issuer

Pursuant to Rule13a-16 or15d-16

of the Securities Exchange Act of 1934

March 25, 2019

GlaxoSmithKline plc	GlaxoSmithKline Capital plc
(Name of registrant)	(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS	980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)	(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form20-F or Form40-F.

Form20-F  ☒            Form40-F  ☐

Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted by RegulationS-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted by RegulationS-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

THIS REPORT ON FORM6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORMF-3 (FILE NOS.333-223982 AND333-223982-02) OF GLAXOSMITHKLINE PLC AND GLAXOSMITHKLINE CAPITAL PLC AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

GlaxoSmithKline plc and GlaxoSmithKline Capital plc. hereby incorporate by reference the following exhibits to this report on Form6-K into their Registration Statement on FormF-3 (File Nos.333-223982,333-223982-02).

Exhibit No.	Description of Document
5.1	Opinion of Cleary Gottlieb Steen & Hamilton LLP, special U.S. counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital plc.
5.2	Opinion of Cleary Gottlieb Steen & Hamilton LLP, special English counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital plc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.

	GlaxoSmithKline plc and
	GlaxoSmithKline Capital plc
		(Registrants)
Date: March 25, 2019
	By:	/s/ Victoria Whyte
		Authorised Signatory for and on behalf of
		GlaxoSmithKline plc and
		GlaxoSmithKline Capital plc

[Signature page to Form6-K]